ARS Pharmaceuticals, Inc. SPRY Deferred Revenue
Deferred Revenue at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityCurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s deferred revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s deferred revenue?
- ARS Pharmaceuticals, Inc. (SPRY) reported deferred revenue of $757K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s deferred revenue changed year-over-year?
- ARS Pharmaceuticals, Inc.'s deferred revenue increased by 40.2% year-over-year, from $540K to $757K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s deferred revenue?
- Over 4 years (2021 to 2025), ARS Pharmaceuticals, Inc.'s deferred revenue has grown at a -19.6% compound annual growth rate (CAGR), from $1.46M to $609K.
- What does deferred revenue mean?
- Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.